OXPHOSight™ Creatine Kinase Assay Kit (CAT#: ITS-1125-HM17)

Quantifies CK enzyme activity.

OXPHOSight

Research-Grade Metabolic Assay Development

The OXPHOSight™ Creatine Kinase Assay Kit quantifies cardiac and skeletal muscle injury markers, which is critical for the safety profiling of statins and other potentially myotoxic pharmaceutical agents. This sensitive kinetic assay enables the early detection of off-target muscle toxicity during drug development. It provides essential data for risk assessment, ensuring that new therapies do not compromise muscle integrity.

Sensitive kinetic assay for quantifying muscle injury biomarkers; Essential for monitoring off-target myotoxicity in statin and kinase inhibitor development.

Myotoxicity Screening

Pre-clinical Safety

Marker for muscle damage (rhabdomyolysis) and myocardial infarction.

Internal performance validation using reference standards under defined assay conditions.

Absorbance at 340 nm

Serum, plasma samples

Cardiology; Muscle Physiology